Targeting the ANG2/TIE2 Axis Inhibits Tumor Growth and Metastasis by Impairing Angiogenesis and Disabling Rebounds of Proangiogenic Myeloid Cells

Amendola, 2009, Regulated and multiple miRNA and siRNA delivery into primary cells by a lentiviral platform, Mol. Ther., 17, 1039, 10.1038/mt.2009.48 Arai, 2004, Tie2/angiopoietin-1 signaling regulates hematopoietic stem cell quiescence in the bone marrow niche, Cell, 118, 149, 10.1016/j.cell.2004.07.004 Augustin, 2009, Control of vascular morphogenesis and homeostasis through the angiopoietin-Tie system, Nat. Rev. Mol. Cell Biol., 10, 165, 10.1038/nrm2639 Bergers, 2008, Modes of resistance to anti-angiogenic therapy, Nat. Rev. Cancer, 8, 592, 10.1038/nrc2442 Brown, 2010, A human monoclonal anti-ANG2 antibody leads to broad antitumor activity in combination with VEGF inhibitors and chemotherapy agents in preclinical models, Mol. Cancer Ther., 9, 145, 10.1158/1535-7163.MCT-09-0554 Casanovas, 2005, Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors, Cancer Cell, 8, 299, 10.1016/j.ccr.2005.09.005 Chae, 2010, Angiopoietin-2 interferes with anti-VEGFR-2-induced vessel normalization and survival benefit in mice bearing gliomas, Clin. Cancer Res., 16, 3618, 10.1158/1078-0432.CCR-09-3073 Chan, 2009, Tumor vasculature is regulated by PHD2-mediated angiogenesis and bone marrow-derived cell recruitment, Cancer Cell, 15, 527, 10.1016/j.ccr.2009.04.010 Chung, 2010, Targeting the tumour vasculature: insights from physiological angiogenesis, Nat. Rev. Cancer, 10, 505, 10.1038/nrc2868 Coffelt, 2010, Elusive identities and overlapping phenotypes of proangiogenic myeloid cells in tumors, Am. J. Pathol., 176, 1564, 10.2353/ajpath.2010.090786 Coffelt, 2010, Angiopoietin-2 regulates gene expression in TIE2-expressing monocytes and augments their inherent proangiogenic functions, Cancer Res., 70, 5270, 10.1158/0008-5472.CAN-10-0012 De Palma, 2003, Targeting exogenous genes to tumor angiogenesis by transplantation of genetically modified hematopoietic stem cells, Nat. Med., 9, 789, 10.1038/nm871 De Palma, 2005, Tie2 identifies a hematopoietic lineage of proangiogenic monocytes required for tumor vessel formation and a mesenchymal population of pericyte progenitors, Cancer Cell, 8, 211, 10.1016/j.ccr.2005.08.002 De Palma, 2008, Tumor-targeted interferon-alpha delivery by Tie2-expressing monocytes inhibits tumor growth and metastasis, Cancer Cell, 14, 299, 10.1016/j.ccr.2008.09.004 DeNardo, 2009, CD4(+) T cells regulate pulmonary metastasis of mammary carcinomas by enhancing protumor properties of macrophages, Cancer Cell, 16, 91, 10.1016/j.ccr.2009.06.018 Du, 2008, HIF1alpha induces the recruitment of bone marrow-derived vascular modulatory cells to regulate tumor angiogenesis and invasion, Cancer Cell, 13, 206, 10.1016/j.ccr.2008.01.034 Ebos, 2009, Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis, Cancer Cell, 15, 232, 10.1016/j.ccr.2009.01.021 Fantin, 2010, Tissue macrophages act as cellular chaperones for vascular anastomosis downstream of VEGF-mediated endothelial tip cell induction, Blood, 116, 829, 10.1182/blood-2009-12-257832 Fiedler, 2004, The Tie-2 ligand angiopoietin-2 is stored in and rapidly released upon stimulation from endothelial cell Weibel-Palade bodies, Blood, 103, 4150, 10.1182/blood-2003-10-3685 Gentner, 2010, Identification of hematopoietic stem cell-specific miRNAs enables gene therapy of globoid cell leukodystrophy, Sci. Transl. Med., 2, 58ra84, 10.1126/scitranslmed.3001522 Hashimoto, 2004, Regulation of tie2 expression by angiopoietin–potential feedback system, Endothelium, 11, 207, 10.1080/10623320490512417 Hashizume, 2010, Complementary actions of inhibitors of angiopoietin-2 and VEGF on tumor angiogenesis and growth, Cancer Res., 70, 2213, 10.1158/0008-5472.CAN-09-1977 Holash, 1999, Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF, Science, 284, 1994, 10.1126/science.284.5422.1994 Huang, 2010, Targeting the ANGPT-TIE2 pathway in malignancy, Nat. Rev. Cancer, 10, 575, 10.1038/nrc2894 Kerbel, 2008, Tumor angiogenesis, N. Engl. J. Med., 358, 2039, 10.1056/NEJMra0706596 Kioi, 2010, Inhibition of vasculogenesis, but not angiogenesis, prevents the recurrence of glioblastoma after irradiation in mice, J. Clin. Invest., 120, 694, 10.1172/JCI40283 Kozin, 2010, Recruitment of myeloid but not endothelial precursor cells facilitates tumor regrowth after local irradiation, Cancer Res., 70, 5679, 10.1158/0008-5472.CAN-09-4446 Lin, 2006, Macrophages regulate the angiogenic switch in a mouse model of breast cancer, Cancer Res., 66, 11238, 10.1158/0008-5472.CAN-06-1278 Mantovani, 2010, Macrophages, innate immunity and cancer: balance, tolerance, and diversity, Curr. Opin. Immunol., 22, 231, 10.1016/j.coi.2010.01.009 Murdoch, 2007, Expression of Tie-2 by human monocytes and their responses to angiopoietin-2, J. Immunol., 178, 7405, 10.4049/jimmunol.178.11.7405 Nasarre, 2009, Host-derived angiopoietin-2 affects early stages of tumor development and vessel maturation but is dispensable for later stages of tumor growth, Cancer Res., 69, 1324, 10.1158/0008-5472.CAN-08-3030 Oliner, 2004, Suppression of angiogenesis and tumor growth by selective inhibition of angiopoietin-2, Cancer Cell, 6, 507, 10.1016/j.ccr.2004.09.030 Paez-Ribes, 2009, Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis, Cancer Cell, 15, 220, 10.1016/j.ccr.2009.01.027 Pucci, 2009, A distinguishing gene signature shared by tumor-infiltrating Tie2-expressing monocytes, blood “resident” monocytes, and embryonic macrophages suggests common functions and developmental relationships, Blood, 114, 901, 10.1182/blood-2009-01-200931 Qian, 2010, Macrophage diversity enhances tumor progression and metastasis, Cell, 141, 39, 10.1016/j.cell.2010.03.014 Saharinen, 2010, How do angiopoietins Tie in with vascular endothelial growth factors?, Curr. Opin. Hematol., 17, 198 Saharinen, 2008, Angiopoietins assemble distinct Tie2 signalling complexes in endothelial cell-cell and cell-matrix contacts, Nat. Cell Biol., 10, 527, 10.1038/ncb1715 Seegar, 2010, Tie1-Tie2 interactions mediate functional differences between angiopoietin ligands, Mol. Cell, 37, 643, 10.1016/j.molcel.2010.02.007 Shojaei, 2007, Tumor refractoriness to anti-VEGF treatment is mediated by CD11b+Gr1+ myeloid cells, Nat. Biotechnol., 25, 911, 10.1038/nbt1323 Shojaei, 2008, Role of Bv8 in neutrophil-dependent angiogenesis in a transgenic model of cancer progression, Proc. Natl. Acad. Sci. USA, 105, 2640, 10.1073/pnas.0712185105 Shojaei, 2010, HGF/c-Met acts as an alternative angiogenic pathway in sunitinib-resistant tumors, Cancer Res., 70, 10090, 10.1158/0008-5472.CAN-10-0489 Stockmann, 2008, Deletion of vascular endothelial growth factor in myeloid cells accelerates tumorigenesis, Nature, 456, 814, 10.1038/nature07445 Suri, 1996, Requisite role of angiopoietin-1, a ligand for the TIE2 receptor, during embryonic angiogenesis, Cell, 87, 1171, 10.1016/S0092-8674(00)81813-9 Takakura, 1998, Critical role of the TIE2 endothelial cell receptor in the development of definitive hematopoiesis, Immunity, 9, 677, 10.1016/S1074-7613(00)80665-2 Venneri, 2007, Identification of proangiogenic TIE2-expressing monocytes (TEMs) in human peripheral blood and cancer, Blood, 109, 5276, 10.1182/blood-2006-10-053504 Xian, 2006, Pericytes limit tumor cell metastasis, J. Clin. Invest., 116, 642, 10.1172/JCI25705